Douglas A. Levine

Merck & Co., Inc., Rahway, NJ, USA (United States)

Full Professor(heuristic)

Ovarian cancer diagnosis and treatment · Reproductive Medicine

h-index128

i10-index318

Publications825

Citations109,032

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 80

Table S4 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Figure S2 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Figure S1 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Table S3 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Table S2 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Figure S4 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Table S1 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Figure S3 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
2025-11-07
Correction: PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma
Cancer Research Communications · 2025-11-01
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Cell · 2025-11-01 · 33 citations
Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Supplemental Fig S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Table 3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Supplemental Table S2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Data from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17
Table 1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid TumorsPreprint
2025-09-17

Open author page on OpenAlex →